新型2型糖尿病亚组显示不同表观遗传模式并与未来糖尿病并发症相关
研究探讨新诊断2型糖尿病四种亚组(SIDD、SIRD、MOD、MARD)间DNA甲基化差异,并构建亚组特异性甲基化风险评分(MRS)在发现和复制队列中验证。亚组特异性MRS与对应亚组及未来并发症相关,MOD-MRS与心血管和肾脏疾病风险降低相关,SIRD-MRS和MARD-MRS与风险增加相关。
要点
- 亚组特异性MRS在对应亚组中显著不同于其他亚组合并组,复制队列验证(OR 1.6-6.1每1-SD增加,P<0.01)。
- 较高MOD-MRS与较低心血管疾病风险(HR 0.65,P=0.001)和肾脏疾病风险(HR 0.50,P<0.001)相关。
- 较高SIRD-MRS和MARD-MRS与这些并发症风险增加相关(HR 1.4-1.9每1-SD增加,P<0.01)。
核心结论
- 研究识别了2型糖尿病亚组间不同的表观遗传模式,这些模式与未来糖尿病并发症相关。
- 数据支持对糖尿病重新分类及2型糖尿病亚组精准医疗的需求。
研究设计与样本
- 研究分析新诊断2型糖尿病受试者血液中全基因组DNA甲基化,在发现队列和复制队列中进行。
- 构建亚组特异性甲基化风险评分(MRS),包括顶级亚组特异性DNA甲基化位点,使用回归模型检验MRS与亚组及未来并发症的关联。
主要发现
- 亚组特异性MRS在分配到各自亚组的患者中与所有其他亚组合并组相比显著不同。
- 这些关联在独立复制队列中验证,显示亚组特异性MRS与个体亚组相关(OR 1.6-6.1每1-SD增加,P<0.01)。
- 较高MOD-MRS与较低心血管疾病风险(HR 0.65,P=0.001)和肾脏疾病风险(HR 0.50,P<0.001)相关。
- 较高SIRD-MRS和MARD-MRS与这些并发症风险增加相关(HR 1.4-1.9每1-SD增加,P<0.01)。
- 亚组特异性MRS包含的95个甲基化位点中,39个注释到先前与糖尿病相关性状相关的基因,包括TXNIP和ELOVL2。
关键数值与推荐
- 亚组特异性MRS与个体亚组相关:OR 1.6-6.1每1-SD增加,P<0.01。
- MOD-MRS与心血管疾病风险:HR 0.65,P=0.001;与肾脏疾病风险:HR 0.50,P<0.001。
- SIRD-MRS和MARD-MRS与并发症风险:HR 1.4-1.9每1-SD增加,P<0.01。
- 亚组特异性MRS包含95个甲基化位点,其中39个注释到糖尿病相关性状基因。
- 18个亚组特异性位点血液甲基化反映肌肉和脂肪组织表观遗传模式。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type 2 diabetes (T2D) was recently reclassified into severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), and mild age-related diabetes (MARD), which have different risk of complications. We explored whether DNA methylation differs between these subgroups and whether subgroup-unique methylation risk scores (MRSs) predict diabetic complications. RESEARCH DESIGN AND METHODS: Genome-wide DNA methylation was analyzed in blood from subjects with newly diagnosed T2D in discovery and replication cohorts. Subgroup-unique MRSs were built, including top subgroup-unique DNA methylation sites. Regression models examined whether MRSs associated with subgroups and future complications. RESULTS: We found epigenetic differences between the T2D subgroups. Subgroup-unique MRSs were significantly different in those patients allocated to each respective subgroup compared with the combined group of all other subgroups. These associations were validated in an independent replication cohort, showing that subgroup-unique MRSs associate with individual subgroups (odds ratios 1.6-6.1 per 1-SD increase, P < 0.01). Subgroup-unique MRSs were also associated with future complications. Higher MOD-MRS was associated with lower risk of cardiovascular (hazard ratio [HR] 0.65, P = 0.001) and renal (HR 0.50, P < 0.001) disease, whereas higher SIRD-MRS and MARD-MRS were associated with an increased risk of these complications (HR 1.4-1.9 per 1-SD increase, P < 0.01). Of 95 methylation sites included in subgroup-unique MRSs, 39 were annotated to genes previously linked to diabetes-related traits, including TXNIP and ELOVL2. Methylation in the blood of 18 subgroup-unique sites mirrors epigenetic patterns in tissues relevant for T2D, muscle and adipose tissue. CONCLUSIONS: We identified differential epigenetic patterns between T2D subgroups that associated with future diabetic complications. These data support a reclassification of diabetes and the need for precision medicine in T2D subgroups.
引用
- Schrader S, Perfilyev A, Ahlqvist E, et al. Novel Subgroups of Type 2 Diabetes Display Different Epigenetic Patterns That Associate With Future Diabetic Complications. Diabetes Care. 2022. PMID: 35607770. doi:10.2337/dc21-2489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。